Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan,
and S-1 as the first-line chemotherapy in patients with advanced gastric cancer.